Business
Licensing Agreement
Licensing Agreement.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n RNS Number : 1407V Proteome Sciences PLC 06 July 2009 \n \n\nMillipore and Proteome Sciences Announce Licensing Agreement \nCompanies to develop innovative research tools to advance the study of Alzheimer's Disease\n\nCobham, UK and Billerica, Ma-July 6, 2009- Proteome Sciences plc (LSE PRM) ('Proteome Sciences' or the 'Company') and Millipore Corporation (NYSE MIL) ('Millipore') today announced that they have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer's disease. Under the terms of the agreement, Millipore will develop Luminex bead-based multiplex immunoassays to measure Proteome Sciences' proprietary Alzheimer's disease biomarkers. The ability to quickly test for these biomarkers will enable researchers to develop new drugs and diagnostics to treat and monitor patients with Alzheimer's.\n\n'We are pleased to be working with Millipore,' said Proteome Sciences' CEO Christopher Pearce. 'We see this as a key step in the development of clinical tests for Alzheimer's disease. These diagnostics will help scientists more precisely diagnose and monitor Alzheimer's disease in its early stages, which are critically important.'\n\nProteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer's disease working in collaboration with the Institute of Psychiatry (IoP) at King's College, London. A number of these biomarkers have been independently identified and their relationship to Alzheimer's disease confirmed by researchers at GlaxoSmithKline.\n\n'This collaboration will help us achieve our broader goal of advancing the study of neurobiology and neurodegenerative diseases,' said Jonathan DiVincenzo, President of Millipore's Bioscience Division. 'By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits. The developme...